|
The company has received permission from CDSCO to import pharmaceutical formulations of new drug in Form CT-20.
Through the said approval, Olaparib film coated tablets of 100mg and 150mg (Lynparza) in combination with abiraterone and prednisone is indicated for the treatment of adult patients with metastatic castration resistant prostate cancer.
The receipt of this permission paves way for the launch of Olaparib film coated tablets of 100mg and 150mg (Lynparza) in India for the above specified additional indication, subject to the receipt of related statutory approvals, if any.
The pharmaceutical company standalone net profit increased 25% to Rs 40.71 crore on 31.7% jump in net sales to Rs 311.07 crore in Q2 FY24 over Q2 FY23.
Astrazeneca Pharma India is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and also provides clinical trial services to an overseas group company.
The company’s consolidated net profit jumped 25% to Rs 40.71 crore on 31.7% increase in net sales to Rs 311.07 crore in Q2 FY24 over Q2 FY23.
The scrip shed 0.16% to Rs 4674.60 on the BSE.
|